GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ANB-030 | ANB030
Compound class:
Antibody
Comment: Rosnilimab (ANB-030; AnaptysBio) is a programmed cell death 1 (PD-1) monoclonal antibody that activates the PD-1 signaling pathway as a mechanism to suppress pathogenic T cell-mediated immune activation for the treatment of autoimmune disorders [1,3-4]. PD-1 agonist monoclonals are claimed in AnaptysBio patent US20220235132 [2]. Peptide sequences for 3.7C6 (APE12095) clones in this patent match the complementarity-determining region (CDR) sequences that form the antigen-binding site of rosnilimab, as annotated by IMGT.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11909 | rosnilimab |
Synonyms ![]() |
| ANB-030 | ANB030 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1282 |
| Other databases | |
| Search PubMed clinical trials | rosnilimab |
| Search PubMed titles | rosnilimab |
| Search PubMed titles/abstracts | rosnilimab |